ECE2017 Guided Posters Diabetes & complications 2 (10 abstracts)
Dipeptidyl peptidase-4 inhibitor therapy and risk of diabetic retinopathy: a population based study
Nam Hoon Kim 1 , Hye Suk Kim 2 , Hye Jin Yoo 1 , Ji A Seo 1 , Nan Hee Kim 1 , Kyung Mook Choi 1 , Sei Hyun Baik 1 , Juneyoung Lee 1 , Jung Hyun Noh 3 & Sin Gon Kim 1
1Korea University College of Meidicine, Seoul, Republic of Korea; 2Anyang SAM Hospital, Anyang, Republic of Korea; 3Inje University College of Medicien, Ilsan, Republic of Korea.
Background: Given the possible association between dipeptidyl peptidase-4 (DPP-4) inhibitor and risk of diabetic retinopathy (DR), we examined whether DPP-4 inhibitors are beneficial or harmful for DR compared with other glucose-lowering agents.
Methods: From a Korean population-based cohort, we identified 67,743 adults with type 2 diabetes treated with oral glucose-lowering agents between 2008 and 2013. Matching (1:1) was done for comparative groups: ever-used (case) and never-used (control) DPP-4 inhibitors (n=14,522 each group). Cox regression analyses assessed the risk of DR events: vitreous hemorrhage, vitrectomy or photocoagulation, intravitreal agent use, and blindness.
Results: During a median follow-up of 28·4 (14.0–45.2) months, there were 305 (control group) and 342 (case group) composite DR events, respectively. Use of DPP-4 inhibitors was not associated with overall risk of composite DR events (adjusted hazard ratio [HR] 1.08, 95% CI 0.93–1.26). Each DR events including vitreous hemorrhage, vitrectomy or photocoagulation, use of intravitreal agents, and blindness were also not increased with DPP-4 inhibitor therapy. The results were consistent according to baseline retinopathy. However, in the analyses by duration of treatment, a DPP-4 inhibitor treatment duration of <12 months was associated with increased risk of composite DR events (adjusted HR 1.95, 95% CI 1.61–2.36).
Conclusion: DPP-4 inhibitor treatment did not increase the overall risk of DR compared with other oral glucose-lowering agents. Given that short-term DPP-4 inhibitor use was associated with increased risk of DR, the need to assess the aggravation of retinopathy in the early phase of DPP-4 inhibitor use is warranted.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more